Surgical Laser Technologies, Inc. Receives FDA Clearance for HemoSleeve.MONTGOMERYVILLE, Pa.--(BUSINESS WIRE)--Sept. 2, 1998--Surgical Laser Technologies, Inc. (NASDAQ/NMS:SLTI) today announced that it has received 510(k) clearance from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to market its internally developed bipolar electrosurgical sheath. The product, which enables hemostasis with the use of microdebriders, will be marketed under the brand name HemoSleeve(TM). The HemoSleeve is approved for use with existing microdebriders that are used in Ear, Nose and Throat surgery (ENT ENT ears, nose, and throat (otorhinolaryngology). ENT abbr. ear, nose, and throat ENT ear, nose and throat. ENT Ears, nose & throat; formally, otorhinolaryngology ). The Company will introduce the product at the meeting of the American Academy of Otolaryngology and Head & Neck Surgery (AAO AAO American Association of Orthodontists; American Academy of Ophthalmology; American Academy of Otolaryngology; American Academy of Osteopathy. AAO ) to be held in San Antonio, Texas “San Antonio” redirects here. For other uses, see San Antonio (disambiguation). San Antonio is the second most populous city in Texas, the third most populous metropolitan area in Texas, and is the seventh most populous city in the United States. As of the 2006 U.S. , September 13th through the 17th. Commenting on the product clearance, Keith Stoneback, SLTs President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. stated: We are excited about presenting the HemoSleeve product at the upcoming AAO and are anxious to receive customer response to this innovative product concept. HemoSleeve represents the first non-laser related product that we have developed internally since our strategic decision to transition our Company to one that serves the needs of the ENT market. HemoSleeve is designed to be compatible with existing ENT microdebriders and enables the surgeon to efficiently provide hemostasis intraoperatively. Powered microdebrider systems are well accepted and widely used in ENT surgery. SLT SLT Salut (French) SLT Sri Lanka Telecom SLT Senior Leadership Team SLT Something Like That SLT Selective Laser Trabeculoplasty SLT South Lake Tahoe (California) SLT Single Line Telephone is a company in transition. Currently, SLT is a worldwide leader in the development, manufacture and marketing of lasers and disposable Contact Laser Delivery Systems that can be used in virtually all general and specialty surgical procedures. SLT markets proprietary Contact Laser Delivery Systems that provide the surgeon with precise and controlled cutting, vaporization vaporization, change of a liquid or solid substance to a gas or vapor. There is fundamentally no difference between the terms gas and vapor, but gas is used commonly to describe a substance that appears in the gaseous state under standard conditions of and coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or of tissue. SLTs mission is to achieve and maintain worldwide leadership in the development, manufacturing and marketing of value-added devices, supplies and therapies used to treat maladies in the head and neck. While focused on this mission, SLT also seeks to leverage its production resources through private label or similar manufacturing arrangements and to exploit its core competencies in other specialties through strategic relationships. Additional information on Surgical Laser Technologies, Inc. and its products can be found on the Companys Web site at www.slti.com . NOTE: The forward-looking statements contained herein reflect managements current views with respect to future events and financial performance. These forward-looking statements including the ability to increase sales and/or benefit from new product developments and supply agreements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, all of which are difficult to predict and many of which are beyond the control of SLT, including but not limited to those risks and uncertainties set forth under the caption Risk Factors in Item 7 of the Companys Form 10-K for the fiscal year ended December 28, 1997. CONTACT: Surgical Laser Technologies Inc. Michael R. Stewart, VP & CFO See Chief Financial Officer. , 215/619-3600 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion